In this session, we join Drs. Peter Kotanko & Bernard Canaud suggest that monthly monitoring of SCI, as part of routine baseline dialysis patient monitoring, will offer a new and cost-effective tool to detect earlier nutritional status deterioration. SCI used as a surrogate marker of active MM would facilitate detection of sarcopenia trends, offering opportunities to implement interventions that might delay, and halt or even reverse such deleterious dynamics. SCI can be easily integrated and used as a first-line tool in complement to visceral proteins (i.e., albumin) to monitor muscle mass changes in clinical routine.